One thousand twenty-four. Numbered. Sealed until inscribed.
Each Cell is a unique non-fungible Algorand Standard Asset (ASA) and a one-of-one by construction. The Cell carries exactly one substantive right: to inscribe one artifact (payload ≤ 4 KB) — its hash written once on-chain and bound to the Cell under a Falcon-1024 signature, verified on-chain by the native AVM falcon_verify opcode (AVM v12 / consensus v41 / go-algorand v4.3.0); the artifact itself is stored off-chain (IPFS/Arweave), tamper-evident against that hash. The cardinality of 1,024 is fixed at genesis under the Algorand zero-address configuration; no minting authority survives the genesis transaction.
32 × 32 = 1,024. Each square is a Cell.
Every Cell wears its own lattice.
Each Cell's mark is generated deterministically from its number — a point lattice with a single lit "short vector" walked through it: the very geometry Falcon's security rests on. It is drawn with SHAKE-256 — the quantum-resistant SHA-3 function Falcon-1024 uses internally — so the art shares its cryptographic root with the post-quantum signature that secures the Cell. Anyone can regenerate a Cell's image from its number alone, and it is the same image the Cell carries at mint. Scrub the full set of 1,024 below.
A Cell exists in one of three states.
The Cell exists on Algorand but has not been inscribed. It is bound to its holder's wallet. It cannot be transferred (if pre-sale) until the next state is reached.
↓ holder inscribes →A 32-byte hash of the artifact (≤ 4 KB) has been signed by the holder's Falcon-1024 key and verified by the contract. The artifact is bound by a write-once inscription to the Cell. The Cell still cannot be transferred (if pre-sale) until 24 months from genesis have elapsed.
↓ time + inscription →The Cell is now freely transferable as a standard Algorand NFT. The inscription travels with it. The verifying public key is on-chain. The artifact's authenticity is publicly checkable for as long as the chain persists.
Three hundred Cells before genesis. The remaining 723 mint at launch.
Informational only · No offer to sell · Pre-sale planned for Q4 2027 · Subject to counsel review, Stiftung formation, FINMA pre-ruling, accredited-investor verification + KYC/AML · Tier pricing indicative and subject to change
The planned Q4 2027 pre-sale is designed to capitalize the protocol: Stiftung formation under the Swiss Civil Code (arts. 80–89-bis), independent smart-contract audit, cryptographer-advisor retainers, and the first twenty-four months of foundation operation. Founder personal capital is zero by deliberate design — codified as a binding stop condition in Section 2 of the founder's commitment letter. No VC tranche. No fungible-token pre-sale. No private allocation. No advisor allocation that precedes the public unlock.
The pre-sale is intended to be offered outside the United States under Regulation S (safe harbor from US registration for offshore distributions) and to US-resident accredited investors under Regulation D 506(c) with verified accreditation. KYC/AML will be mandatory for every buyer regardless of jurisdiction. Maximum two Cells per natural person, cumulative across tiers — a per-buyer cap structured to dispersion, not accumulation. Final offering terms will be set by counsel-prepared subscription documents at launch; nothing on this page constitutes an offer to sell or a solicitation of an offer to buy securities.
Pre-sale Cells are non-transferable until both conditions are met.
Conjunction, not disjunction. A pre-sale Cell sealed for twenty-four months remains non-transferable. A pre-sale Cell inscribed on day one remains non-transferable for twenty-four months. The lock is enforced in the inscription contract at the protocol level — not as policy, not as undertaking, not as social expectation. Because the underlying ASA is non-transferable for the bootstrap window, every higher-order derivative (lending, fractionalization, wrapping, AMM-pooling) is also impossible. The structural intent is to remove secondary-market investment behavior from the pre-sale cohort during the issuer-effort period — which is the supervisory concern that drives Anlagetoken re-characterization under FINMA's 2018 framework.
Genesis-day Cells (#302 → #1024) carry no transferability lock. They are freely transferable from issuance and the inscription mechanism is the only gate they encounter.
What this page is, and what it is not.
Not an offer. This page describes the planned Vault Cell structure for informational purposes only. It is not an offer to sell, a solicitation of an offer to buy, or a recommendation regarding any security, token, or financial instrument. Tier prices, supply allocations, and dates are indicative and subject to change. Final offering terms will be set by counsel-prepared subscription documents at portal launch.
No rights other than inscription. Cells do not confer ownership of the Foundation, profit rights, dividend rights, voting rights, redemption rights, or any claim against the Foundation or any third party. The right of inscription is a technical capability bound to the Cell by the inscription contract, not a financial right. Cells are not securities by design; final classification is subject to FINMA pre-ruling and counsel review.
Cell classification. The Cells are structured with the intent of supporting a Nutzungstoken (utility-token) classification under FINMA's 2018 ICO Guidelines and the 2019 Stablecoin Supplement — built around utility-at-issuance, a conjunctive transferability lock, and a per-buyer cap of two Cells. Final classification is subject to a FINMA pre-ruling and counsel review and is not yet final.
Jurisdiction. The planned pre-sale is intended to be made (a) outside the United States under Regulation S, and (b) to verified accredited investors in the United States under Regulation D Rule 506(c). It will not be made to non-accredited US persons or to residents of any jurisdiction where its publication, availability, or use would be unlawful — including persons or entities listed under OFAC, EU, UK, or Swiss SECO sanctions programmes.
Forward-looking statements. Statements regarding the Stiftung incorporation, the Q4 2027 Cell pre-sale, the Q2 2028 genesis, the transferability lock, and the future behavior of the inscription contract are forward-looking. They reflect current expectations and are subject to risks, uncertainties, and changes — including counsel review, regulatory pre-rulings, technical feasibility, market conditions, and the discretion of the Stiftungsrat once seated. Actual outcomes may differ materially. See /invest for the full investor-facing disclosure stack.